Related Experiment Video
Updated: May 12, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
No association between MGP rs1800802 polymorphism and stenosis of the coronary artery
Abazar Roustazadeh1, Mohammad Najafi, Abdollah Amirfarhangi
1Biochemistry Department, Tehran University of Medical Sciences, Tehran 141761351, Iran. A-Roustazadeh@razi.tums.ac.ir
Background And Objectives:
Matrix Gla protein (MGP) was originally isolated from bone but it is known to be expressed in several tissues including kidney, lung, heart, cartilage and vascular smooth muscle cells (VSMC) of the blood vessel wall. Since it inhibits calcification in subendothelial space of vessels thus, we evaluated the association of rs1800802(T > C) polymorphism and stenosis of the coronary artery.
Design And Setting:
Cross-sectional case-control.
Subjects And Methods:
One hundred eighty two subjects recruited on the basis of study protocol from who underwent coronary angiography. The controls (n=70) had normal coronary arteries (up to 5% stenosis). The patients (n=112) subdivided into three subgroups; single-vessel disease (SVD), two-vessel disease (2VD) and three-vessel disease (3VD) based on the number of stenosed coronary vessels (at least 50% stenosis). rs1800802 (T > C) polymorphism was determined by PCR-RFLP technique.
Results:
Genotype distribution was not significant between control and patient groups. In addition, there were no significant differences between rs1800802 (T > C) frequency and gender (P=.092), and also patient subgroups (one-, two- and three vessel disease) (P=.840).
Conclusion:
We concluded that rs1800802 (T > C) polymorphism within the MGP promoter is not related to stenosis of the coronary artery.
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Single Nucleotide Polymorphisms-SNPs
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease II: Pathophysiology
